Eli Lilly And Stock Fundamentals
| LLY Stock | USD 806.14 12.79 1.56% |
Eli Lilly and fundamentals help investors to digest information that contributes to Eli Lilly's financial success or failures. It also enables traders to predict the movement of Eli Stock. The fundamental analysis module provides a way to measure Eli Lilly's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eli Lilly stock.
At this time, Eli Lilly's Discontinued Operations is fairly stable compared to the past year. Reconciled Depreciation is likely to rise to about 1.6 B in 2024, whereas Depreciation And Amortization is likely to drop slightly above 941.5 M in 2024. Eli | Select Account or Indicator |
Eli Lilly and Company Return On Asset Analysis
Eli Lilly's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Eli Lilly Return On Asset | 0.14 |
Most of Eli Lilly's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eli Lilly and is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Eli Total Assets
Total Assets |
|
Based on the latest financial disclosure, Eli Lilly and has a Return On Asset of 0.1395. This is 101.59% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The return on asset for all United States stocks is 199.64% lower than that of the firm.
Eli Lilly Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Eli Lilly's current stock value. Our valuation model uses many indicators to compare Eli Lilly value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Eli Lilly competition to find correlations between indicators driving Eli Lilly's intrinsic value. More Info.Eli Lilly and is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers reporting about 0.21 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Eli Lilly and is roughly 4.68 . At this time, Eli Lilly's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Eli Lilly's earnings, one of the primary drivers of an investment's value.Eli Lilly's Earnings Breakdown by Geography
Eli Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eli Lilly's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eli Lilly could also be used in its relative valuation, which is a method of valuing Eli Lilly by comparing valuation metrics of similar companies.Eli Lilly is currently under evaluation in return on asset category among its peers.
Eli Lilly ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Eli Lilly's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Eli Lilly's managers, analysts, and investors.Environmental | Governance | Social |
Eli Fundamentals
| Return On Equity | 0.65 | ||||
| Return On Asset | 0.14 | ||||
| Profit Margin | 0.20 % | ||||
| Operating Margin | 0.40 % | ||||
| Current Valuation | 752.77 B | ||||
| Shares Outstanding | 949.32 M | ||||
| Shares Owned By Insiders | 0.15 % | ||||
| Shares Owned By Institutions | 83.73 % | ||||
| Number Of Shares Shorted | 5.79 M | ||||
| Price To Earning | 54.92 X | ||||
| Price To Book | 55.31 X | ||||
| Price To Sales | 19.02 X | ||||
| Revenue | 34.12 B | ||||
| Gross Profit | 21.91 B | ||||
| EBITDA | 12.46 B | ||||
| Net Income | 5.24 B | ||||
| Cash And Equivalents | 2.07 B | ||||
| Cash Per Share | 2.97 X | ||||
| Total Debt | 25.23 B | ||||
| Debt To Equity | 1.58 % | ||||
| Current Ratio | 1.13 X | ||||
| Book Value Per Share | 15.82 X | ||||
| Cash Flow From Operations | 4.24 B | ||||
| Short Ratio | 2.19 X | ||||
| Earnings Per Share | 9.11 X | ||||
| Price To Earnings To Growth | 0.78 X | ||||
| Target Price | 1007.68 | ||||
| Number Of Employees | 43 K | ||||
| Beta | 0.42 | ||||
| Market Capitalization | 777.42 B | ||||
| Total Asset | 64.01 B | ||||
| Retained Earnings | 10.31 B | ||||
| Working Capital | (1.57 B) | ||||
| Current Asset | 12.57 B | ||||
| Current Liabilities | 8.23 B | ||||
| Annual Yield | 0.01 % | ||||
| Five Year Return | 1.83 % | ||||
| Net Asset | 64.01 B | ||||
| Last Dividend Paid | 5.03 |
About Eli Lilly Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eli Lilly and's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eli Lilly using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eli Lilly and based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 16.7 B | 17.5 B | |
| Total Revenue | 34.1 B | 35.8 B | |
| Cost Of Revenue | 6.6 B | 3.6 B | |
| Stock Based Compensation To Revenue | 0.02 | 0.01 | |
| Sales General And Administrative To Revenue | 0.20 | 0.32 | |
| Research And Ddevelopement To Revenue | 0.27 | 0.17 | |
| Capex To Revenue | 0.22 | 0.23 | |
| Revenue Per Share | 37.91 | 39.80 | |
| Ebit Per Revenue | 0.30 | 0.28 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Eli Stock Analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.